Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 141

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 141
---
disparity in coverage among various payers or among various healthcare plans offered by a single payer; •payer medical management requirements, including prior authorization requirements; •differing information and billing requirements among payers; •failure by patients or healthcare providers to provide complete and correct billing information; and •limitations and requirement for patient billing, including those related to deductibles, co -payments, and co -insuranceoriginating from contracts with commercial payers. Moreover, our ability to collect payment for our tests and testing services in a timely manner or at all from our customers may decline to the extent we expand our business into new customer groups, including individual physicians, nutritionists and other practitioners, from which collection rates are often significantly lower than distributors in the health industry and which involve substantial additional risks that are discussed in these risk factors below. Our collection risks also include the potential for default or bankruptcy by the party responsible for payment and other risks associated with payment collection generally. Any inability to maintain our past payment collection levels could cause our revenue and ability to achieve profitability to decline and adversely affect our business, prospects and financial condition. The uncertainty of receiving payment for our tests and complex laboratory billing processes could negatively affect our business, financial condition, results of operations and growth prospects. We may incur significant losses from fraud. We may in the future incur losses from various types of fraud, including stolen credit card numbers, claims that a customer did not authorize a purchase and customers who have closed bank accounts or have insufficient bank accounts to satisfy payments. We provide our Rewell genetic tests as direct -to -customerto the general population, currently constituting 5% of our total revenue. In Argentina, we accept payment via bank transfer, credit card payments, and cryptocurrency. Although we have measures in place to detect and reduce the occurrence of fraudulent activity on our platforms, those measures may not always be effective. In addition to the direct costs of such losses, if the fraud is related to credit card transactions and becomes excessive, it could potentially result in us paying higher fees or losing the right to accept credit cards for payment. In addition, under current credit card practices, we are liable for fraudulent credit card transactions because we do not obtain a cardholder’s signature for online purchases on our platform. Our failure to adequately prevent fraudulent transactions could damage our reputation, result in litigation or regulatory action and additional expenses which all could negatively affect our business, financial condition, results of operations and growth prospects. Our pricing strategies may not meet customers’ price expectations or may adversely affect our revenues. Our pricing